FOSTER CITY, Calif.--(BUSINESS WIRE)--Recent recalls in the pharmaceutical industry have increased awareness of the need to improve contaminant and impurity analysis in drug manufacturing. Biopharmaceutical companies are responding to this challenge for products produced in cell culture to include in-process contaminant and impurity analysis for rapid detection of the smallest known self-replicating organism, called Mycoplasma. To assist in these efforts to address the presence of contamination, Applied Biosystems Inc. (NYSE:ABI) is introducing a new molecular-based system to detect Mycoplasma rapidly and accurately during biopharmaceutical manufacturing.
